Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. Other stock markets 15/07/2026			5-day change	1st Jan Change
969.77 ^PKR	+0.16%		-4.02%	-5.16%

05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI
04-30	Highnoon Laboratories Limited Approves Final Cash Dividend for the Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	51,382	-	-
Change	-	11.36%	-5.16%	-	-
Enterprise Value (EV)	48,650	54,175	51,382	51,382	51,382
Change	-	11.36%	-5.16%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.69x	1.5x	1.34x
EV / Revenue	-	0x	1.69x	1.5x	1.34x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.64%	5.36%	6.19%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	969.77	969.77	969.77
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/03/25	07/04/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.65%	185M
ELI LILLY AND COMPANY	34.25x	12.25x	25.43x	0.59%	1,031B
JOHNSON & JOHNSON	27.09x	6.22x	16.9x	2.1%	595B
ABBVIE INC.	30.33x	7.27x	14.9x	2.81%	431B
ROCHE HOLDING AG	17.47x	4.34x	10.68x	3.06%	326B
NOVARTIS AG	21.17x	5.44x	13.17x	2.9%	277B
ASTRAZENECA PLC	20.69x	4.37x	12.08x	2.02%	263B
NOVO NORDISK A/S	13.99x	5.26x	10.84x	3.55%	224B
AMGEN INC.	23.3x	6.19x	10.94x	2.84%	193B
GILEAD SCIENCES, INC.	-46.85x	5.61x	31x	2.5%	164B
Average	15.72x	6.33x	16.22x	2.7%	350.45B
Weighted average by Cap.	23.26x	7.66x	17.87x	2.04%